RGD-modified AAV vector

**RGD-modified AAV vector** is a genetically engineered variant of adeno-associated virus (AAV), a non-enveloped single-stranded DNA virus widely used as a delivery vehicle in gene therapy. This vector is modified by inserting an *Arg-Gly-Asp (RGD)* peptide—typically into the viral capsid protein sequence (such as VP3)—to enable the virus to target and infect cells expressing integrin receptors, independent of the native heparan sulfate proteoglycan (HSPG) binding[1][2][4]. The RGD motif modification expands the tissue tropism of the AAV vector, facilitating gene transfer into integrin-expressing cells, including those that lack HSPG, such as certain tumor cells and muscle cells[1][3][4]. The modification has shown enhanced transduction efficiency in muscle-directed gene therapy and in cell types previously resistant to standard AAV vectors[4]. RGD-modified AAV vectors are experimental tools and have been proposed for treatment of cancers, genetic diseases, and muscle disorders. They are not currently commercialized under any brand or trade name. Primary development and research are conducted by academic institutions and gene therapy laboratories.

Other names

RGD-AAVRGD-modified adeno-associated virusRGD-modified rAAVRGD peptide-modified AAV